These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10169389)

  • 1. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation.
    Johnson RE; Hornbrook MC; Hooker RS; Woodson GT; Shneidman R
    Pharmacoeconomics; 1997 Jul; 12(1):76-88. PubMed ID: 10169389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic consequences of NSAID-induced gastropathy: the French context.
    de Pouvourville G
    Scand J Rheumatol Suppl; 1992; 96():49-53. PubMed ID: 1439624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands.
    Herings RM; Klungel OH
    Pharmacoeconomics; 2001; 19(6):655-65. PubMed ID: 11456213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care resource utilization and costs of NSAID-induced gastrointestinal toxicity. A population-based study in Switzerland.
    Delcò F; Michetti P; Beglinger C; Fried M; Szucs TD
    Digestion; 2004; 69(1):10-9. PubMed ID: 14755148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville.
    Knill-Jones RP
    Scand J Rheumatol Suppl; 1992; 96():59-62. PubMed ID: 1439626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic consequences of NSAID-induced gastrointestinal damage.
    de Pouvourville G; Tasch RF
    Eur J Rheumatol Inflamm; 1993; 13(1):33-40. PubMed ID: 7821337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The iatrogenic costs of NSAID therapy: a population study.
    Sturkenboom MC; Romano F; Simon G; Correa-Leite ML; Villa M; Nicolosi A; Borgnolo G; Bianchi-Porro G; Mannino S
    Arthritis Rheum; 2002 Apr; 47(2):132-40. PubMed ID: 11954006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastropathy induced by nonsteroidal anti-inflammatory drugs: prescribing patterns among geriatric practitioners.
    Pertusi RM; Godwin KS; House JK; Knebl JA; Alexander JH; Rubin BR; Forman MD
    J Am Osteopath Assoc; 1999 Jun; 99(6):305-10. PubMed ID: 10405516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.
    Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
    Arthritis Rheum; 2000 Apr; 43(4):917-24. PubMed ID: 10765939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients.
    Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
    Br J Clin Pharmacol; 2001 Aug; 52(2):185-92. PubMed ID: 11488776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs.
    Smalley WE; Griffin MR; Fought RL; Ray WA
    J Gen Intern Med; 1996 Aug; 11(8):461-9. PubMed ID: 8872783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A decision analysis model in the evaluation of NSAIDs in a managed care setting: a case study.
    Brixner DI
    Med Interface; 1994 Nov; 7(11):145-50. PubMed ID: 10138701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of NSAID gastropathy in elderly patients. An observational study in general practice and nursing homes.
    van Leen MW; van der Eijk I; Schols JM
    Age Ageing; 2007 Jul; 36(4):414-8. PubMed ID: 17537740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of NSAID-induced gastropathy in Sweden.
    Jönsson B; Haglund U
    Scand J Gastroenterol; 2001 Jul; 36(7):775-9. PubMed ID: 11444479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From peptic ulcer disease to NSAID gastropathy. An evolving nosology.
    Roth SH
    Drugs Aging; 1995 May; 6(5):358-67. PubMed ID: 7647425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-efficiency of nonsteroidal anti-inflammatory drug prescribing in Zagreb, Croatia.
    Vukusić I; Stimac D; Culig J
    Coll Antropol; 2005 Jun; 29(1):143-7. PubMed ID: 16117313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs.
    Rahme E; Barkun AN; Adam V; Bardou M
    Drug Saf; 2004; 27(13):1019-42. PubMed ID: 15471508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis.
    Fendrick AM; Bandekar RR; Chernew ME; Scheiman JM
    Arthritis Rheum; 2002 Feb; 47(1):36-43. PubMed ID: 11932876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
    Spiegel BM; Chiou CF; Ofman JJ
    Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy.
    Ma J; Yang XY; Qiao L; Liang LQ; Chen MH
    J Dig Dis; 2008 May; 9(2):79-83. PubMed ID: 18419640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.